Sanofi India Limited has informed the Exchange regarding a press release dated May 14, 2025, titled "Sanofi India Limited declares 4% growth in net sales & 27% growth in operating profits in Q1-2025".
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi India reported its Q1 2025 results (quarter ended March 31, 2025), with revenue from operations at ₹5,359 million, up about 4.9% year-on-year on a comparable continuing business basis (the company demerged its Consumer Healthcare business effective June 1, 2024, which is now shown as discontinued operations). Operating profit (revenue from operations minus total expenses) jumped 27% YoY to approximately ₹162 crores, driven by lower overall expenses and operating efficiencies, while profit from continuing operations surged roughly 66% to ₹1,195 million (EPS of ₹51.89 vs ₹31.26). The company highlighted steady growth of its newly launched diabetes drug Soliqua® and reiterated its 'India for India' strategy focused on innovation and operating efficiency. The board approved the unaudited results, which were also subject to a limited review by statutory auditors, with no qualifications flagged in the filing.
A positive set of numbers for shareholders – top-line growth was modest but operating profit and net profit from continuing operations expanded sharply, reflecting better cost control and likely boosting near-term investor sentiment. The clean limited review and focus on margin expansion are constructive signals for the stock.